Tara Lynn  Kieffer net worth and biography

Tara Kieffer Biography and Net Worth

Tara L. Kieffer, Ph.D. joined Enanta in December 2020. Prior to Enanta, Dr. Kieffer was at Vertex Pharmaceuticals where she held roles of increasing responsibility. Most recently, she was Vice President, External Innovation, Business Development where she was responsible for assessing the external innovation landscape and leading projects aimed at identifying in-licensing and acquisition opportunities. Prior to that, she was Vice President, Integrated Program Management, after being Senior Director, Chief of Staff to the Chief Medical Officer. Dr. Kieffer also held the positions of Director, Clinical Biomarkers and Head of Clinical Virology where she built and led a team responsible for laboratory and clinical research studies to understand the development of antiviral drug resistance to Hepatitis C and influenza viruses. Before joining Vertex, Dr. Kieffer was at Johns Hopkins University School of Medicine in the Department of Molecular Biology and Genetics, where her research studies focused on ongoing replication in patients with well-suppressed Human Immunodeficiency Virus infection.

Dr. Kieffer graduated summa cum laude from Colgate University with a B.A. in Molecular Biology. She holds a Ph.D. in Immunology from Johns Hopkins University School of Medicine. She is co-author on more than 50 publications and an inventor on multiple patents involving treatments for Hepatitis.

What is Tara Lynn Kieffer's net worth?

The estimated net worth of Tara Lynn Kieffer is at least $419.95 thousand as of December 5th, 2025. Kieffer owns 30,620 shares of Enanta Pharmaceuticals stock worth more than $419,953 as of April 28th. This net worth evaluation does not reflect any other investments that Kieffer may own. Learn More about Tara Lynn Kieffer's net worth.

How do I contact Tara Lynn Kieffer?

The corporate mailing address for Kieffer and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Tara Lynn Kieffer's contact information.

Has Tara Lynn Kieffer been buying or selling shares of Enanta Pharmaceuticals?

Tara Lynn Kieffer has not been actively trading shares of Enanta Pharmaceuticals in the last ninety days. Most recently, Tara Lynn Kieffer sold 2,106 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a transaction totalling $29,968.38. Following the completion of the sale, the insider now directly owns 30,620 shares of the company's stock, valued at $435,722.60. Learn More on Tara Lynn Kieffer's trading history.

Who are Enanta Pharmaceuticals' active insiders?

Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Kathleen Capps (Insider), Tara Kieffer (Insider), Jay Luly (CEO), Brendan Luu (Insider), Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ), Yat Or (Insider), and Scott Rottinghaus (Insider). Learn More on Enanta Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Enanta Pharmaceuticals?

During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 11,961 shares worth more than $170,149.14. The most recent insider tranaction occured on December, 5th when insider Kathleen S Capps sold 323 shares worth more than $4,596.29. Insiders at Enanta Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Enanta Pharmaceuticals.

Information on this page was last updated on 12/5/2025.

Tara Lynn Kieffer Insider Trading History at Enanta Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2025Sell2,106$14.23$29,968.3830,620View SEC Filing Icon  
12/6/2024Sell2,283$8.06$18,400.9829,305View SEC Filing Icon  
6/17/2024Sell7,266$12.33$89,589.7832,341View SEC Filing Icon  
See Full Table

Tara Lynn Kieffer Buying and Selling Activity at Enanta Pharmaceuticals

This chart shows Tara Lynn Kieffer's buying and selling at Enanta Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals logo
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $13.71
Low: $13.26
High: $13.78

50 Day Range

MA: $13.55
Low: $12.08
High: $15.41

2 Week Range

Now: $13.71
Low: $4.96
High: $17.15

Volume

102,662 shs

Average Volume

182,022 shs

Market Capitalization

$397.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99